whatshot

NUVL   $94.92  2.36% Market Closed After Close 94.93 0.01%

Nuvalent Inc
show_chart Advanced Chart of NUVL
Last Events:

2023-10-04 The hottest instrument.

2023-08-09 Trend pattern changed from канал to расширяющаяся формация.

2023-08-09 Signal in RSI changed from bearish reversal to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-08-06 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-08-06 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-05 Trend pattern changed from сужающийся канал to канал.

2023-08-05 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-04 Trend pattern changed from расширяющийся канал to сужающийся канал.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 12
Target Price Mean 115.50
Mean unverified/preliminary 115.50 / 115.50
Target Price Low / High 100.00 / 137.00
Median / STD DEV 112.50 / 13.85
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Buy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None Sell None
stoch Sell None None
ma20 Sell ActivelyBuy ActivelyBuy
ma50 Sell None None
ma100 None Buy ActivelyBuy
Candlestick PatternNov. 19, 2024 Bullish Belt Hold - is a candlestick that has a long white body and small shadows. It opens on the low of the day. It occurs in a downtrend. Considered to be a bullish reversal pattern.
ISIN US6707031075
ceo Dr. James R. Porter Ph.D.
Website https://www.nuvalent.com
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.